Johnson & Johnson released information earlier today that the Food and Drug Administration did not approve its antipsychotic medication Risperdal (risperidone) for use as a treatment for psychotic symptoms in Alzheimer disease.
Full U.S. prescribing information for Risperdal can be found at a number of locations on the Web, including, if you click here, this webpage.
-
Anthony H. Risser | neuroscience | neuropsychology | brain | neurology | alzheimer disease
Full U.S. prescribing information for Risperdal can be found at a number of locations on the Web, including, if you click here, this webpage.
-
Anthony H. Risser | neuroscience | neuropsychology | brain | neurology | alzheimer disease
Comments